Daily Time of Radiation Treatment Is Associated with Subsequent Oral Mucositis Severity during Radiotherapy in Head and Neck Cancer Patients.
Aged
Chemoradiotherapy
/ adverse effects
Circadian Rhythm
/ physiology
Dose Fractionation, Radiation
Female
Head and Neck Neoplasms
/ therapy
Humans
Male
Middle Aged
Mouth Mucosa
/ drug effects
Photoperiod
Prospective Studies
Radiation Injuries
/ diagnosis
Self Report
Severity of Illness Index
Stomatitis
/ diagnosis
Time Factors
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
12
08
2019
revised:
25
11
2019
accepted:
20
02
2020
pubmed:
27
2
2020
medline:
8
7
2021
entrez:
27
2
2020
Statut:
ppublish
Résumé
Limited treatment options are available for oral mucositis, a common, debilitating complication of cancer therapy. We examined the association between daily delivery time of radiotherapy and the severity of oral mucositis in patients with head and neck cancer. We used electronic medical records of 190 patients with head and neck squamous cell carcinoma who completed radiotherapy, with or without concurrent chemotherapy, at Roswell Park Comprehensive Cancer Center (Buffalo, NY) between 2015 and 2017. Throughout a 7-week treatment course, patient mouth and throat soreness (MTS) was self-reported weekly using a validated oral mucositis questionnaire, with responses 0 (no) to 4 (extreme). Average treatment times from day 1 until the day before each mucositis survey were categorized into seven groups. Multivariable-adjusted marginal average scores (LSmeans) were estimated for the repeated- and maximum-MTS, using a linear-mixed model and generalized-linear model, respectively. Radiation treatment time was significantly associated with oral mucositis severity using both repeated-MTS ( We report a significant association between radiation treatment time and oral mucositis severity in patients with head and neck cancer. Although additional studies are needed, these data suggest a potential simple treatment time solution to limit severity of oral mucositis during radiotherapy without increasing cost.
Sections du résumé
BACKGROUND
Limited treatment options are available for oral mucositis, a common, debilitating complication of cancer therapy. We examined the association between daily delivery time of radiotherapy and the severity of oral mucositis in patients with head and neck cancer.
METHODS
We used electronic medical records of 190 patients with head and neck squamous cell carcinoma who completed radiotherapy, with or without concurrent chemotherapy, at Roswell Park Comprehensive Cancer Center (Buffalo, NY) between 2015 and 2017. Throughout a 7-week treatment course, patient mouth and throat soreness (MTS) was self-reported weekly using a validated oral mucositis questionnaire, with responses 0 (no) to 4 (extreme). Average treatment times from day 1 until the day before each mucositis survey were categorized into seven groups. Multivariable-adjusted marginal average scores (LSmeans) were estimated for the repeated- and maximum-MTS, using a linear-mixed model and generalized-linear model, respectively.
RESULTS
Radiation treatment time was significantly associated with oral mucositis severity using both repeated-MTS (
CONCLUSIONS
We report a significant association between radiation treatment time and oral mucositis severity in patients with head and neck cancer.
IMPACT
Although additional studies are needed, these data suggest a potential simple treatment time solution to limit severity of oral mucositis during radiotherapy without increasing cost.
Identifiants
pubmed: 32098893
pii: 1055-9965.EPI-19-0961
doi: 10.1158/1055-9965.EPI-19-0961
pmc: PMC7898770
mid: NIHMS1567433
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
949-955Subventions
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Mol Cell Endocrinol. 2012 Feb 5;349(1):91-104
pubmed: 21939733
Science. 2018 Mar 16;359(6381):
pubmed: 29439024
Sci Transl Med. 2018 Sep 12;10(458):
pubmed: 30209245
Cancer Invest. 2002;20(5-6):793-800
pubmed: 12197238
JAMA. 2019 Apr 16;321(15):1481-1490
pubmed: 30990550
FEBS Lett. 2010 Jun 18;584(12):2618-25
pubmed: 20227409
Cancer Nurs. 2002 Dec;25(6):461-7; quiz 468-9
pubmed: 12464838
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6835-40
pubmed: 23569261
Pharmacol Rev. 2017 Apr;69(2):161-199
pubmed: 28351863
J Invest Dermatol. 1991 Aug;97(2):273-80
pubmed: 1830075
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):E2106-15
pubmed: 23690597
Cancer. 2006 Jan 15;106(2):329-36
pubmed: 16342066
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Biochemistry. 2015 Jan 20;54(2):110-23
pubmed: 25302769
Nat Rev Cancer. 2004 Apr;4(4):277-84
pubmed: 15057287
Clin Oncol (R Coll Radiol). 2017 Apr;29(4):231-238
pubmed: 28034487
Cancer. 2007 May 1;109(9):1914-22
pubmed: 17377917
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3407-12
pubmed: 15689397
Am J Pathol. 2001 May;158(5):1793-801
pubmed: 11337377
J Biol Chem. 2008 Feb 22;283(8):4535-42
pubmed: 18086663
World J Clin Oncol. 2012 Apr 10;3(4):57-62
pubmed: 22553505
Ann Oncol. 2012 Dec;23(12):3110-3116
pubmed: 22745214
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Cancer. 2008 Sep 15;113(6):1446-52
pubmed: 18683883
Annu Rev Pharmacol Toxicol. 2010;50:377-421
pubmed: 20055686
Handb Exp Pharmacol. 2013;(217):261-88
pubmed: 23604483
Cell Cycle. 2005 Jul;4(7):901-7
pubmed: 15917646
Ann Med. 2014 Jun;46(4):191-207
pubmed: 24915535
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1592-9
pubmed: 23267082
Cancer. 2008 Nov 15;113(10):2704-13
pubmed: 18973181
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Cancer. 2003 Jan 1;97(1):155-69
pubmed: 12491517
Chronobiol Int. 2019 Mar;36(3):332-342
pubmed: 30557062
Bone Marrow Transplant. 2006 Feb;37(4):393-401
pubmed: 16415901
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):166-72
pubmed: 18805649
Int J Radiat Biol. 2009 Jun;85(6):504-9
pubmed: 19412843
Science. 2003 Oct 10;302(5643):255-9
pubmed: 12934012